90Y and 177Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy

Bioconjugate Chemistry

Volumn 12, Issue 4, 2001, Pages 559-568

  Liu, S ^a   Cheung, E ^a   Ziegler, M C ^a   Rajopadhye, M ^a   Edwards, D S ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORINE COMPOUNDS; TRACE ELEMENTS;

ACETATE BUFFERS; AMMONIUM ACETATE; ARG GLY ASPS; BUFFER PH; CARBOXYMETHYL; LABELINGS; RADIOLABELLING; RECEPTOR ANTAGONISTS; TUMOR THERAPY; VITRONECTIN;

CHELATION;

EID: 0034921224     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc000146n     Document Type: Article

References (60)

1. 99mTc using aminocarboxylates as co-ligands
2. 99mTc-chelator-peptide conjugates
3. 99mTc-chelator-peptide conjugates
4. 99mTc-labeling of highly potent small peptides
5. 99mTc
6. 99mTc
7. 99mTc
8. 99mTc-labeling hydrazones of a hydrazinonicotinamide conjugated cyclic peptide
9. RP463: A stabilized technetium-99m complex of a hydrazino nicotinamide conjugated chemotactic peptide for infection imaging
10. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals
11. Technetium complexes of a hydrazinonicotinamide-conjugated cyclic peptide and 2-hydrazinopyridine: Synthesis and characterization
12. Leukotriene B4 antagonists modified with amino acid "ast end" and technetium-99m chelators for imaging of sites of inflammation and infection
13. The rapid detection of inflammation and infection using Tc-99m labeled LTB4 antagonists
14. 4 antagonist which incorporates the ligand into the binding site
15. 111In complexes of cyclic RGD-peptide antagonists of the integrin αvβ3
16. Structural and functional aspect of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists
17. Therapeutic radiopharmaceuticals
18. Angiogenesis in cancer, vascular, rheumatoid and other disease
19. Biochemical interactions of tumor cells with the basement membrance
20. Mechanism of angiogenesis in vascular disorders: Potential therapeutic targets
21. Tumor angiogenesis correlates with metastatic disease, N-myc-amplification, and poor outcome in human neuroblastoma
22. Angiogenesis and colonization in tumor metastatic process: Basis and applied advances
23. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
24. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis
25. Vascular integrin αvβ3: A new prognostic indicator in breast cancer
26. Clinical applications of angiogenic growth factors and their inhibitors
27. Angiogenesis and antiangoegenesis: Perspectives for the treatment of solid tumors
28. Tumor angiogenesis-new drug on the block
29. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
30. Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: New drugs in cancer therapy
31. Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy
32. An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization
33. Arg-Gly-Asp constrained within cyclic pentapeptides strong and selective inhibitors of cell adhension to vitronectin and laminin fragment P1
34. RGD-peptides for tumor targeting: Biological evaluation of radioiodinated analogues and introduction of a novel glycosylated peptide with improved biokinetics
35. Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor imaging
36. Criteria for the selection of the most desirable radionuclide for radiolabeling of monoclonal antibodies
37. Vehicles, chelators, and radionuclides: Chossing the "building blocks" of an effective therapeutic radioimmunoconjugate
38. Tumor targeting with radiolabeled macrocycle-antibody conjugates
39. Radiolabeling of monoclonal antibodies with metal chelates
40. Copper chelates as probes of biological systems: Stable copper complexes with macrocyclic bifunctional chelating agent
41. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid and study of its yttrium(III) complex
42. Synthesis and characterization of the gadolinium(3+) complex of DOTA-propylamide: A model DOTA-protein conjugate
43. Carboxymethyl-substituted bifunctiona chelators: Preparation of aryl isothionate derivatives of 3-(carboxymethyl)-3-azapentanedioic acid, 3,12-bis(carboxymethyl)-6,9-dioxa-3,12-diazatetradecanedioic acid, and 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid for use as protein labels
44. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates
45. A facile, water soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates
46. Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator
47. A new convenient synthesis of bifunctional chelating agent 1-(4-aminobenzyl)-1,4,8,11-tetraazacyclotetradecane-N,N′,N″, N‴-tetraacetic acid [1-(H2NBn-TETA)]
48. Optimized conditions for chelation of yittrium-90-DOTA immunoconjugates
49. Maleimidocycteineamido-DOTA derivatives: New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions
50. Sammarium-153 and lutetium-177 chelation properties of selected macrocyclic and cyclic ligands
51. 90Y]Bz-DTPA-oct: A yttrium-90-labeled oactreotide analogue for radiotherapy of somatostatin receptor-positive tumors
52. Radiometal-labeled macrocyclic chelator-derived somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal therapy
53. Metal complexes of cyclic tetra-azatetraacetic acids
54. Synthesis, stability, and structure of gadolinium(III) and yttrium(III) macrocyclic poly(amino carboxylates)
55. Equilibrium and kinetic studies of lanthanide complexes of macrocyclic polyamino carboxylates
56. Stabilities of the alkaline earth and divalent transition metal complexes of the tetraazamacrocyclic tetraacetic acid ligands
57. Stabilities of trivalenet metal ion complexes of the tetraacetate derivatives of 12-, 13-, and 14-membered tetraazamacrocycles
58. 99mTc-labeled bioconjugates
59. NMR studies of the metal loading kinetics and acid-base chemistry of DOTA and butylamide-DOTA
60. 90Y with 1, 4, 7, 10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), a model for cancer radioimmunotherapy